Equity · Healthcare
ACAD
NASDAQACADIA Pharmaceuticals (ACAD)
The line runs 29.40 USD on 10 August through 21.23 USD on 6 November, on a scale from 15 to 35. Days the market did not trade hold the previous close, flat.
- Market cap
- 3.7B USD
- P/E (TTM)
- 10.0
- Revenue, year to Dec 2025
- 1.1B USD
- EPS, diluted, year to Dec 2025
- 2.30 USD
- 52-week range
- 18.62 USD – 30.58 USD
- Avg volume
- 134.4K
as of Nov 6, 2026
Have ACADIA Pharmaceuticals (ACAD) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, ACADIA Pharmaceuticals insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 10 Nov 2025, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 30 Oct 2026
Buys 0Sells 1Net sold $69KOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Oct 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Sell | 3,321 | 69K USD |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Oct 2026 | Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | Award | 6,815 |
Which funds hold ACADIA Pharmaceuticals (ACAD)?
1 of the 45 institutional funds we track reported a ACADIA Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 14.3M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 711,352 | 14.3M USD | +1.7% |
Have members of Congress traded ACADIA Pharmaceuticals (ACAD)?
The most recent congressional trade disclosed in ACADIA Pharmaceuticals is a sale by Sara Jacobs (house, CA), dated 16 Jun 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 16 Jun 2022 | Sara Jacobshouse · Democrat–CA | Sale | 1K USD–15K USD | 42 days |
What has been filed or recorded for ACADIA Pharmaceuticals (ACAD)?
The filings we hold for ACADIA Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.31 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.8B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.4B USD | at period end |
| 24 Sep 2026 | Fails to deliver | Shares failed to deliver | 6,765 shares | 172K USD notional · 0.004% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.18 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.02 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 2.30 USD | |
| 31 Dec 2025 | Financials | Revenue | 1.1B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 391.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 2.30 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.42 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.16 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.11 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 1.36 USD |
ACADIA Pharmaceuticals (ACAD): frequently asked questions
What did ACADIA Pharmaceuticals shares close at?
ACADIA Pharmaceuticals closed at 21.23 USD on 6 Nov 2026, down 0.02% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is ACADIA Pharmaceuticals’ market cap?
ACADIA Pharmaceuticals is worth 3.7B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is ACADIA Pharmaceuticals’ P/E ratio?
ACADIA Pharmaceuticals has a price-to-earnings ratio of 10.0, as of 6 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is ACADIA Pharmaceuticals’ revenue?
ACADIA Pharmaceuticals reported revenue of 1.1B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have ACADIA Pharmaceuticals insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, ACADIA Pharmaceuticals insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 10 Nov 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own ACADIA Pharmaceuticals?
1 of the 45 funds we track reported a ACADIA Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded ACADIA Pharmaceuticals?
Yes. 1 trade in ACADIA Pharmaceuticals appears in the congressional disclosures we hold: a sale by Sara Jacobs (House, CA) dated 16 Jun 2022, filed 28 Jul 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did ACADIA Pharmaceuticals last report earnings?
ACADIA Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.31 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings